Gain Therapeutics Announced The Presentation Of New Evidence Supporting The Disease-modifying Activity Of Gt-02287 In Preclinical Animal Models Of Both GBA-1 And Idiopathic Parkinson's Disease
Gain Therapeutics to Participate at Upcoming Investor Conferences
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8
BTIG Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $10
Gain Therapeutics Shares Are Trading Lower. The Company Announced the Presentation of a Late-breaking Abstract at the International Congress of Parkinson's Disease and Movement Disorders.